# Targeting lipophagy and nuclear receptors in metabolic-associated fatty liver disease: insights from traditional Chinese medicine

**Authors:** Ting Yue, Nafei Huang, Ziming Zhao, Lili Yu, Xiaoming He, Xiao Yu, Yi Zheng

PMC · DOI: 10.3389/fphar.2025.1744069 · Frontiers in Pharmacology · 2026-02-03

## TL;DR

This paper explores how traditional Chinese medicine can treat fatty liver disease by targeting specific liver processes and receptors, offering safer and more effective treatments.

## Contribution

The paper systematically reviews TCM compounds that target the NR-lipophagy axis for MAFLD treatment, highlighting their multi-target mechanisms and therapeutic potential.

## Key findings

- Herbal metabolites modulate nuclear receptors to regulate lipolysis, reduce oxidative stress, and suppress inflammation in MAFLD.
- Herbal compounds synergistically activate fatty acid oxidation while repressing lipogenesis, improving MAFLD outcomes.
- TCM agents show promise as low-side-effect therapies for MAFLD through NR-associated signaling pathways and lipophagy induction.

## Abstract

Background: Metabolic associated fatty liver disease (MAFLD) represents a globally prevalent chronic hepatic disorder hallmarked by excessive lipid accumulation within hepatocytes. This condition can progressively deteriorate to cirrhosis and hepatocellular carcinoma, thereby imposing a substantial healthcare burden. Numerous laboratory studies confirm that drugs targeting the nuclear receptor (NR)-lipophagy axis exhibit preventive and therapeutic potential for MAFLD. However, most remain confined to animal and cell models, and no specific MAFLD therapies are clinically available. In contrast, traditional Chinese medicine (TCM) has garnered considerable interest due to its unique theoretical framework and clinical efficacy in MAFLD management. Purpose: This article systematically reviews existing herbal compounds, extracts, and active metabolites that target the NR-lipophagy interaction for MAFLD treatment. It aims to facilitate the development of low-side-effect herbal formulations and offer valuable insights for future research on the NR-lipophagy axis. Method: Search terms including “MAFLD”, “nuclear receptor”, “lipophagy”, “Compound Traditional Chinese Medicine”, “active metabolites”, “natural products”, and “disease” were combined for literature retrieval. Result: As modulators of pleiotropic NRs, certain herbal metabolites mimic endogenous ligands to exert regulatory lipolysis effects—synergistically modulating lipid metabolism, mitigating oxidative stress, and suppressing inflammation during MAFLD intervention. Herbal compound preparations modulate the NR-lipophagy axis via multi-target, multi-pathway mechanisms: moderately activating fatty acid (FA) oxidation pathways while repressing lipogenesis, thereby achieving sustained amelioration of MAFLD. Conclusion: TCM (including herbal compound preparations, extracts, and active metabolites) exerts therapeutic effects on MAFLD by inducing lipophagy through diverse pharmacological mechanisms and NR-associated signaling pathways. These agents emerge as promising focal points for MAFLD basic research and potential candidates for MAFLD drug development, offering reduced side effects and enhanced therapeutic efficacy.

## Linked entities

- **Diseases:** cirrhosis (MONDO:0005155), hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Genes:** Lpl (lipoprotein lipase) [NCBI Gene 16956], Gnmt (glycine N-methyltransferase) [NCBI Gene 14711], PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, Tfe3 (transcription factor E3) [NCBI Gene 209446] {aka F830016E06Rik, Tcfe3, Tfe-3, bHLHe33, mTFE3}, Gpbar1 (G protein-coupled bile acid receptor 1) [NCBI Gene 227289] {aka BG37, GPCR, GPR131, M-BAR, TGR5}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Atg3 (autophagy related 3) [NCBI Gene 67841] {aka 2610016C12Rik, APG3, Apg3l, Atg3l, PC3-96}, Tfeb (transcription factor EB) [NCBI Gene 21425] {aka Tcfeb, bHLHe35}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, Fasn (fatty acid synthase) [NCBI Gene 14104] {aka A630082H08Rik, FAS}, SPNS1 (SPNS lysolipid transporter 1, lysophospholipid) [NCBI Gene 83985] {aka HSpin1, LAT, PP2030, SLC62A1, SLC63A1, SPIN1}, Lipa (lysosomal A, lysosomal acid type) [NCBI Gene 16889] {aka Lal, Lip-1, Lip1}, DNASE2 (deoxyribonuclease 2, lysosomal) [NCBI Gene 1777] {aka AIPCS, DNASE2A, DNL, DNL2}, Fgf21 (fibroblast growth factor 21) [NCBI Gene 56636] {aka Fgf8c}, Sesn2 (sestrin 2) [NCBI Gene 230784] {aka HI95, SEST2, Ses2}, Pnpla2 (patatin-like phospholipase domain containing 2) [NCBI Gene 66853] {aka 0610039C21Rik, 1110001C14Rik, Atgl, TTS-2.2}, ATG13 (autophagy related 13) [NCBI Gene 9776] {aka KIAA0652, PARATARG8}, Cpt1a (carnitine palmitoyltransferase 1a, liver) [NCBI Gene 12894] {aka C730027G07, CPTI, Cpt1}, LIPE (lipase E, hormone sensitive type) [NCBI Gene 3991] {aka AOMS4, FPLD6, HSL, LHS, REH}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, Vdr (vitamin D (1,25-dihydroxyvitamin D3) receptor) [NCBI Gene 22337] {aka Nr1i1}, Lcat (lecithin cholesterol acyltransferase) [NCBI Gene 16816] {aka D8Wsu61e}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, Fkbp1a (FK506 binding protein 1a) [NCBI Gene 14225] {aka FKBP12, Fkbp, Fkbp1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Apo (anterior polar opacity) [NCBI Gene 104237], FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Rptor (regulatory associated protein of MTOR, complex 1) [NCBI Gene 74370] {aka 4932417H02Rik, Rap, Raptor, mKIAA1303}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, Tsc2 (TSC complex subunit 2) [NCBI Gene 22084] {aka Nafld, Tcs2}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, Mcoln2 (mucolipin 2) [NCBI Gene 68279] {aka 3300002C04Rik, TRPML2}, Acaca (acetyl-Coenzyme A carboxylase alpha) [NCBI Gene 107476] {aka A530025K05Rik, Acac, Acc1, Gm738}, Gh (growth hormone) [NCBI Gene 14599] {aka Gh1, Ghb1}, Abcg5 (ATP binding cassette subfamily G member 5) [NCBI Gene 27409] {aka cmp, sterolin-1, trac}, Ambra1 (autophagy/beclin 1 regulator 1) [NCBI Gene 228361] {aka 2310079H06Rik, A130023A14, D030051N19Rik, mKIAA1736}, Foxo1 (forkhead box O1) [NCBI Gene 56458] {aka Afxh, FKHR, Fkhr1, Foxo1a}, Lipg (lipase G, endothelial type) [NCBI Gene 16891] {aka 3110013K01Rik, EL, lipase, mEDL}, Nr1h3 (nuclear receptor subfamily 1, group H, member 3) [NCBI Gene 22259] {aka LXR, RLD1, Unr1}, Atg13 (autophagy related 13) [NCBI Gene 51897] {aka 1110053A20Rik, D2Ertd391e, Harbi1}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Abcg1 (ATP binding cassette subfamily G member 1) [NCBI Gene 11307] {aka Abc8, White}, Scarb1 (scavenger receptor class B, member 1) [NCBI Gene 20778] {aka CD36, Cd36l1, Chohd1, Cla-1, Cla1, D5Ertd460e}, Rab32 (RAB32, member RAS oncogene family) [NCBI Gene 67844] {aka 2810011A17Rik}, ULK2 (unc-51 like autophagy activating kinase 2) [NCBI Gene 9706] {aka ATG1B, Unc51.2}, Ppargc1a (peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) [NCBI Gene 19017] {aka A830037N07Rik, Gm11133, PGC-1, PPARGC-1-alpha, Pgc-1alpha, Pgc1}, Thrb (thyroid hormone receptor beta) [NCBI Gene 21834] {aka Nr1a2, T3R[b], T3Rbeta, Thrb1, Thrb2, c-erbAbeta}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, Atg14 (autophagy related 14) [NCBI Gene 100504663] {aka 4832427M01, Atg14L, D14Ertd114e, D14Ertd436e}, Akap6 (A kinase anchor protein 6) [NCBI Gene 238161] {aka Akapalpha, Akapbeta, PRKA}, NR0B2 (nuclear receptor subfamily 0 group B member 2) [NCBI Gene 8431] {aka SHP, SHP1}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, Dnm2 (dynamin 2) [NCBI Gene 13430] {aka Dyn2, Udnm, b2b2159Clo}, Atg12 (autophagy related 12) [NCBI Gene 67526] {aka 4931423H11Rik, A330058M13Rik, Apg12l, Atg12l}, ATG101 (autophagy related 101) [NCBI Gene 60673] {aka C12orf44}
- **Diseases:** type 2 diabetes (MESH:D003924), lymphoma (MESH:D008223), liver inflammatory damage (MESH:D056486), myalgia (MESH:D063806), liver injury (MESH:D017093), glucose tolerance (MESH:D018149), hepatocellular carcinoma (MESH:D006528), hepatic lipid (MESH:D011017), anemia (MESH:D000740), atherosclerotic (MESH:D050197), infections (MESH:D007239), AKH (MESH:C565870), insulin resistance (MESH:D007333), rashes (MESH:D005076), Metabolic associated fatty liver disease (MESH:D005234), nausea (MESH:D009325), skin cancer (MESH:D012878), NASH (MESH:D005235), overweight (MESH:D050177), diarrhea (MESH:D003967), bile stasis (MESH:D014647), metabolic disease (MESH:D008659), pruritus (MESH:D011537), vomiting (MESH:D014839), HOPS (MESH:C562646), gastrointestinal symptoms (MESH:D012817), hepatic inflammation (MESH:D007249), hepatic disorder (MESH:D008107), cirrhosis (MESH:D005355), oral ulcers (MESH:D019226), hyperglycemia (MESH:D006943), dyslipidemia (MESH:D050171), mitochondrial dysfunction (MESH:D028361), SCD (MESH:C536778), NAFLD (MESH:D065626), malignancies (MESH:D009369), lactic acidosis (MESH:D000140), gallstone (MESH:D042882), DFLGN (MESH:D002062)
- **Chemicals:** polyphenol (MESH:D059808), ATP (MESH:D000255), steroid (MESH:D013256), Palmitic acid (MESH:D019308), DC (MESH:D003841), Fibrates (MESH:D058607), lipid (MESH:D008055), OCA (MESH:C464660), Oleic Acid (MESH:D019301), alisol B 23-acetate (MESH:C526957), glucose (MESH:D005947), anthraquinone (MESH:D000880), flavonoid (MESH:D005419), BA (MESH:D001464), BBR (MESH:D001599), Alpha-naphthyl isothiocyanate (MESH:D015058), Chinese medicine (-), Bile acids (MESH:D001647), phosphatidylethanolamine (MESH:C483858), Saikosaponin (MESH:C025759), Atractylenolide I (MESH:C424804), chenodeoxycholic acid (MESH:D002635), Emodin (MESH:D004642), FA (MESH:D005227), Dihydromyricetin (MESH:C472036), Metformin (MESH:D008687), FFAs (MESH:D005230), T0901317 (MESH:C423915), 20-Hydroxyecdysone (MESH:D004441), PI3P (MESH:C055525), Micheliolide (MESH:C577928), Resveratrol (MESH:D000077185), Rhein (MESH:C020491), phenoxyisobutyric acid (MESH:C010285), cholesterol (MESH:D002784), Nuciferine (MESH:C008692), fat (MESH:D005223), Methionine (MESH:D008715), Silymarin (MESH:D012838), Didymin (MESH:C552234), Galangin (MESH:C037032), CPT (MESH:C000708228), Paeonol (MESH:C013638), lactate (MESH:D019344), choline (MESH:D002794), GW4064 (MESH:C412815), Quercetin (MESH:D011794), TG (MESH:D014280), rapamycin (MESH:D020123), Thiazolidinedione (MESH:C089946)
- **Species:** Codonopsis pilosula (species) [taxon 86864], Veratrum album (white false hellebore, species) [taxon 50243], Magnolia figo (species) [taxon 13612], Atractylodes macrocephala (species) [taxon 265785], Citrus reticulata (mandarin orange, species) [taxon 85571], Homo sapiens (human, species) [taxon 9606], Rheum palmatum (species) [taxon 137221], Nekemias grossedentata (species) [taxon 416090], Alpinia officinarum (Chinese-ginger, species) [taxon 199623], Mus musculus (house mouse, species) [taxon 10090], Crataegus (hawthorn, genus) [taxon 23159]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12910217/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12910217/full.md

## References

134 references — full list in the complete paper: https://tomesphere.com/paper/PMC12910217/full.md

---
Source: https://tomesphere.com/paper/PMC12910217